晚期卵巢癌微创间歇性肿瘤减灭术后同日出院
该研究基于2010-2021年美国癌症委员会认证项目数据,纳入3464例接受新辅助化疗后微创间歇性肿瘤减灭术的晚期上皮性卵巢癌患者,分析同日出院(SDD)的趋势及结局。SDD比例从2010年1.3%升至2021年14.8%,年均增加0.75个百分点(95%CI 0.34%-1.16%)。SDD与30天再入院(aOR 0.58,95%CI 0.14-1.67)及90天死亡率(aOR 0.43,95%CI 0.024-2.07)无显著关联。
要点
- 晚期卵巢癌MI-IDS后SDD比例逐年上升,2021年达14.8%。
- SDD组30天再入院率2.4%,90天死亡率1.6%,与住院组相近。
- 多因素分析未发现SDD与再入院或死亡风险显著相关。
核心结论
- 自2010年以来,晚期卵巢癌患者MI-IDS后SDD比例持续增长;SDD与30天再入院或90天术后死亡率无显著关联,但受样本量小、事件率低及选择偏倚限制,无法得出确定性结论。
研究设计与样本
- 回顾性队列研究,纳入2010-2021年间在癌症委员会认证项目接受诊疗、新辅助化疗后行MI-IDS的晚期上皮性卵巢癌患者3464例。
主要发现
- 3464例中363例(10.5%)接受SDD,比例从2010年1.3%升至2021年14.8%,年均增加0.75个百分点(95%CI 0.34%-1.16%)。
- 与住院患者相比,SDD患者更年轻(63.8 vs 65.1岁,p=0.04)、更多居住于高收入邮编区(42.7% vs 35.2%,p=0.005)、IV期比例更高(50.7% vs 43.1%,p=0.01)、IDS后无残留病灶比例更高(52.6% vs 40.5%,p<0.001)、更多来自东北部(20.4% vs 16.7%)或西部(25.1% vs 20.7%,p<0.001)及大都市地区(87.9% vs 83.0%,p=0.04)。
- SDD组与住院组的30天再入院率分别为2.4%和2.9%,90天死亡率分别为1.6%和1.7%。
- 多因素分析显示,SDD与30天再入院(aOR 0.58,95%CI 0.14-1.67)及90天死亡率(aOR 0.43,95%CI 0.024-2.07)无显著关联。
临床怎么用
- 对于经过选择的晚期卵巢癌MI-IDS患者,SDD可能是可行的出院模式,但需结合患者特征及医疗资源审慎评估。
局限性
- 样本量小、事件率低及选择偏倚限制了确定性结论的得出。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To describe the use of and outcomes after same day discharge (SDD) after minimally invasive interval debulking surgery (MI-IDS) for advanced epithelial ovarian cancer (EOC). METHODS: We identified patients diagnosed with advanced EOC between 2010 and 2021 who received care in Commission on Cancer Accredited programs and underwent MI-IDS following neoadjuvant chemotherapy. We quantified trends in SDD and its association with patient, clinical, and hospital characteristics. We estimated associations between SDD and 30-day readmissions and 90-day postoperative mortality using univariable and multivariable logistic regression. RESULTS: Of 3464 patients, 363 (10.5%) underwent SDD, increasing from 1.3% in 2010 to 14.8% in 2021 (average annual increase 0.75 percentage points; 95% CI 0.34% - 1.16%). Compared with admitted patients, those underwent SDD were younger (63.8 vs 65.1 years, p = 0.04), resided in high income zip codes (42.7% vs 35.2%, p = 0.005), had stage IV disease (50.7% vs 43.1%, p = 0.01), had no residual disease after IDS (52.6% vs 40.5%, p < 0.001), received care in the Northeast (20.4% vs 16.7%) or West (25.1% vs 20.7%, p < 0.001) regions and in metropolitan locations (87.9% vs 83.0%, p = 0.04). Readmission and 90-day mortality were uncommon among those undergoing SDD (2.4% and 1.6%) and admission (2.9% and 1.7%), respectively. After controlling for additional factors, SDD after MI-IDS was not associated with 30-day readmissions (adjusted odds ratio (aOR) 0.58, 95% CI 0.14-1.67) nor 90-day mortality (aOR 0.43, 95% CI 0.024-2.07). CONCLUSIONS: Since 2010, a growing proportion of patients have undergone SDD after MI-IDS for advanced ovarian cancer. While SDD was not associated with readmission or postoperative mortality, our small sample size, low event rates, and selection bias limit definitive conclusions.
引用
- Tewari S, Youssef A, Li S, et al. Same day discharge after minimally invasive interval debulking surgery in advanced stage ovarian cancer. Gynecol Oncol. 2026. PMID: 41740456. doi:10.1016/j.ygyno.2026.02.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。